Anixa Biosciences (ANIX) announced that the second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the company’s novel chimeric antigen receptor-T cell therapy for recurrent ovarian cancer. Patients in the fourth cohort are receiving a dose of three million CAR-positive cells per kilogram of body weight-representing a 30-fold increase over the initial dose level. To date, no dose-limiting toxicities have been observed in the fourth cohort. The ongoing first-in-human clinical trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy. The Phase 1 study is designed to evaluate safety, determine the maximum tolerated dose, and monitor initial signals of clinical activity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences issued additional U.S. patent for CAR-T technology
- Anixa Biosciences: Promising Developments and Strong Intellectual Property Bolster Buy Rating
- Anixa plans to begin Phase 2 of breast cancer vaccine trial
- Anixa receives Notice of Allowance for breast cancer technology patent in Canada
- Anixa Biosciences Receives Buy Rating Amidst Strong Patent Portfolio and Promising Vaccine Trials